This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Traficet-EN, GSK1605786A, GSK1605786, GSK'786, CCX282-B, CCX282
Description: Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD.
ChemoCentryx and GSK
In August 2006, ChemoCentryx and GSK's Center of Excellence for External Drug Discovery (CEEDD) entered into a multiproduct strategic alliance for the discovery, development and commercialization of novel medicines targeting four defined chemokine and chemoattractant receptors for the treatment of a variety ofinflammatory disorders.
Under the terms of the agreement, ChemoCentryx is responsible for the discovery and development of up to six small molecule drug candidates across four targets through clinical proof-of-concept, at which point GSK will have exclusive options to license each product for further development and commercialization on a worldwide basis.
In January 2010, GSK and ChemoCentryx announced that GSK exercised its option to obtain an exclusive license for further development and worldwide commercialisation of Traficet-EN for the treatment of inflammatory bowel diseases, including Crohn's disease. The option also encompasses two...See full deal structure in Biomedtracker
Additional information available to subscribers only: